Sort by

Send to

Choose Destination

Search results

Items: 6


Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators.

N Engl J Med. 2003 Nov 13;349(20):1893-906. Epub 2003 Nov 10. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.


Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.

Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D; Melagatran for Thrombin inhibition in Orthopaedic surgery.

Lancet. 2002 Nov 9;360(9344):1441-7.


A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.

Eriksson BI, Wille-Jørgensen P, Kälebo P, Mouret P, Rosencher N, Bösch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P.

N Engl J Med. 1997 Nov 6;337(19):1329-35.


Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment.

Kälebo P, Ekman S, Lindbratt S, Eriksson BI, Pauli U, Zachrisson BE, Close P.

Thromb Haemost. 1996 Dec;76(6):893-6.


Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.

Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P.

Thromb Haemost. 1994 Aug;72(2):227-31.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk